SOURCE: Skinvisible, Inc.

Skinvisible, Inc.

November 05, 2013 14:31 ET

Skinvisible Adds Innovative Sunless Tanning Products Available for Exclusive Licensing

Invisicare® Suppresses Odor Associated With Sunless Formulations

LAS VEGAS, NV--(Marketwired - Nov 5, 2013) - Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) is pleased to announce that is has successfully developed new additions to its sunless tanning product line formulated with its patented Invisicare® polymer delivery technology. Skinvisible's sunless products address all of the issues which are common with sunless tanning products, specifically odor, streaking and the longevity of the tan. In addition to the innovation in sunless tanning formulating, Skinvisible has developed two new forms of application to add to its pipeline of sunless tanning products including innovative mousse and continuous spray formulations.

Skinvisible's sunless tanning products address the problems long associated with sunless tanning products. A key problem with applying sunless tanning is the unpleasant odor that is produced during application and the "processing" time. The odor is due to the chemical reaction between the dihydroxyacetone (DHA) and the skin. Many products on the market use fragrances to try to mask the odor which in many cases just exasperates the smell of the product. Skinvisible products do not contain fragrances that try to cover-up the smell; instead due to the chemical make-up of Invisicare, the odor produced stays suppressed and neutralized within the polymer.

"We have studies which have proven that when Invisicare is used in sunless tanning products, it has the ability to suppress the odor of the DHA and retain moisture in the skin, providing a much longer lasting tan than products currently on the market," said Terry Howlett, President and CEO. "This added benefit provides consumers with a tan that lasts 50% to 70% longer." He added, "We have also addressed ease of application with our Skinvisible's formulations. Along with our lotions and professional spray formulations, we have added a new mousse formulation and an innovative continuous spray which allows you to spray from all angles, even upside down and backwards. Unlike aerosols, Skinvisible's continuous spray does not use harmful propellants."

The sunless tanner / self tanning market is growing exponentially. The market of US produced sunless tanning products reached $609 million in 2012 and is forecasted to reach $940 million by 2016 according to IBIS World. The reason for the growth is attributed to consumers' concern regarding the health risks such as skin cancer and the government implementing stricter regulations regarding tanning beds. These consumers are turning to self tanning as a convenient alternative and are searching for longer-lasting tans with convenient application methods without the odor. Skinvisible's formulations have addressed all of these needs.

Skinvisible is seeking exclusive licensees for its high quality, unique sunless tanning products. The product line consists of light, medium and dark lotions, mousse and sprays along with moisturizing "after-sun" products all with patent protection and benefits that will resonate with consumers.

About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. and .

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2013).

Contact Information

  • Corporate Contact:
    Doreen McMorran
    Skinvisible Pharmaceuticals, Inc.
    Phone: 702-433-7154